Document is current
Any future updates will be listed below
-
Authors
Haratake, Naoki
Takamori, Shinkichi
Isozaki, Hideko https://orcid.org/0000-0003-0124-996X
Shigeta, Keisuke
Kikutake, Chie
Ozawa, Hiroki https://orcid.org/0000-0002-3771-7940
Bhattacharya, Atrayee
Nakashoji, Ayako https://orcid.org/0000-0003-2443-6995
Suyama, Mikita https://orcid.org/0000-0001-9526-3193
Takenaka, Tomoyoshi
Yoshizumi, Tomoharu https://orcid.org/0000-0002-4497-1816
Osoegawa, Atsushi
Hata, Aaron N. https://orcid.org/0000-0002-6127-318X
Kufe, Donald https://orcid.org/0000-0001-5743-8888
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health () CA97098, CA233084, CA282437 and CA262134)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA249291, CA137008, CA164273 and CA265826)
- License Information
-
More Information
Article History
Received: 15 February 2025
Revised: 5 July 2025
Accepted: 30 July 2025
First Online: 8 August 2025
Competing interests
: DK has equity interests in Genus Oncology and is a paid consultant to CanBas. The other authors declared no potential conflicts of interest. ANH has received grants/research support from Amgen, Blueprint Medicines, BridgeBio, Bristol-Myers Squibb, C4 Therapeutics, Eli Lilly, Novartis, Nuvalent, Pfizer, Roche/Genentech, and Scorpion Therapeutics; and has served as a compensated consultant for Engine Biosciences, Nuvalent, Oncovalent, TigaTx, and Tolremo Therapeutics. The other authors have no competing interests.
: This study did not involve human participants or live vertebrate animals. Ethical approval and informed consent were not required.
: All authors have read and approved the final manuscript and agree to its publication.
